USA vs. IBB, HTGC, DNP, ADX, PTY, NUV, GSBD, GAB, RVT, and TY
Should you be buying Liberty All-Star Equity Fund stock or one of its competitors? The main competitors of Liberty All-Star Equity Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), Nuveen Municipal Value Fund (NUV), Goldman Sachs BDC (GSBD), The Gabelli Equity Trust (GAB), Royce Value Trust (RVT), and Tri-Continental (TY). These companies are all part of the "investment offices, not elsewhere classified" industry.
Liberty All-Star Equity Fund (NYSE:USA) and iShares Biotechnology ETF (NASDAQ:IBB) are both finance companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.
Given iShares Biotechnology ETF's higher probable upside, analysts plainly believe iShares Biotechnology ETF is more favorable than Liberty All-Star Equity Fund.
Liberty All-Star Equity Fund received 164 more outperform votes than iShares Biotechnology ETF when rated by MarketBeat users. Likewise, 68.87% of users gave Liberty All-Star Equity Fund an outperform vote while only 67.09% of users gave iShares Biotechnology ETF an outperform vote.
Liberty All-Star Equity Fund has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, iShares Biotechnology ETF has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.
In the previous week, Liberty All-Star Equity Fund had 1 more articles in the media than iShares Biotechnology ETF. MarketBeat recorded 4 mentions for Liberty All-Star Equity Fund and 3 mentions for iShares Biotechnology ETF. iShares Biotechnology ETF's average media sentiment score of 0.80 beat Liberty All-Star Equity Fund's score of 0.62 indicating that iShares Biotechnology ETF is being referred to more favorably in the news media.
Liberty All-Star Equity Fund pays an annual dividend of $0.66 per share and has a dividend yield of 9.8%. iShares Biotechnology ETF pays an annual dividend of $0.40 per share and has a dividend yield of 0.3%.
9.9% of Liberty All-Star Equity Fund shares are held by institutional investors. Comparatively, 62.5% of iShares Biotechnology ETF shares are held by institutional investors. 0.1% of Liberty All-Star Equity Fund shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Liberty All-Star Equity Fund beats iShares Biotechnology ETF on 7 of the 11 factors compared between the two stocks.
Get Liberty All-Star Equity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for USA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding USA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Liberty All-Star Equity Fund Competitors List
Related Companies and Tools
